RCRunfeng Chen

Runfeng Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Runfeng Chen has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • An Qin

    Department of Orthopaedics, Shanghai Key Laboratory of Orthopaedic Implant, Shanghai Ninth People' s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China

    1 shared publication
  • Baoqiang Li

    Institute for Advanced Ceramics State Key Laboratory of Urban‐rural Water Resource and Environment Harbin Institute of Technology Harbin P. R. China

    1 shared publication
  • Guanxiong Liu

    Institute for Advanced Ceramics; State Key Laboratory of Urban Water Resource and Environment, Harbin Institute of Technology, Harbin 150001, China

    1 shared publication
  • Jinmin Zhao

    Guangxi Key Laboratory of Regenerative Medicine, Guangxi Medical University, Guangxi, China

    1 shared publication
  • Qian Liu

    Guangxi Key Laboratory of Regenerative Medicine, Guangxi Medical University, Guangxi, China

    1 shared publication
  • Wenxin He

    Shanghai Key Laboratory of Orthopaedic Implants

    1 shared publication

Latest Publications

  • Chitosan derived nitrogen-doped carbon dots suppress osteoclastic osteolysisviadownregulating ROS

    by Runfeng Chen, Guanxiong Liu, Xiaochen Sun, Xiankun Cao, Wenxin He, Xixi Lin, Qian Liu, Jinmin Zhao, Yichuan Pang, Baoqiang Li, et al.

    Osteoclasts are the main cells involved in normal bone remodeling and pathological bone destruction in vivo. Overactivation of osteoclasts can lead to osteolytic diseases, including breast cancer, bone tumors, arthritis, the aseptic loosening of orthopedic implants, and Paget's disease. Excessive reactive oxygen species are the main cause of osteoclast overactivation. We have synthesized chitosan derived nitrogen-doped carbon dots (N-CDs) with a high synthetic yield and the ability to scavenge reactive oxygen species (ROS). N-CDs effectively abrogated RANKL-induced elevation in ROS generation and therefore impaired the activation of NF-κB and MAPK pathways. Osteoclastogenesis and bone resorption was effectively attenuated in vitro. Furthermore, the in vivo administration of N-CDs in mice protected them against lipopolysaccharide (LPS)-induced calvarial bone destruction and breast cancer cell-induced tibial bone loss. Based on the good biocompatibility of N-CDs and the ability to efficiently remove ROS, a nanomaterial treatment scheme was provided for the first time for the clinical treatment of osteolytic diseases.